- Total revenues of €174.7 million in line with guidance, including €157.9 million in product sales
- Strong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt refinancing and a 21% reduction in operating cash burn
- 2026 to be a potentially transformational year with Phase 3 Lyme disease data expected in the first half of the year
Lyon (France), March 18, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its audited consolidated financial results for the year ended December 31, 2025, provided corporate updates and confirmed its financial guidance for 2026[1] . The Company also announced the filing of its annual report on Form 20-F and Universal registration document (URD) for the financial year ended December 31, 2025 with the U.S. Securities and Exchange Commission (SEC) and the French financial market authority (Autorité des marchés financiers or AMF), respectively. The full-year 2025 consolidated financial results are available on the Company’s website (Financial Reports – Valneva) [2].
To access the full release, please click on the PDF below.